Funding
Chemkart India Puts ₹97.90 Lakh Into Easy Raw Materials Rights Issue for Unit Setup
By News Desk ·
Key takeaways
- Chemkart India invested ₹97.90 lakh in wholly owned subsidiary Easy Raw Materials Private Limited through a rights issue.
- The rights issue allotted 1,83,000 equity shares of ₹10 face value at ₹53.50 per share, keeping Chemkart's stake at 100%.
- Easy Raw Materials reported nil turnover and a ₹59.47 lakh loss after tax as of March 31, 2026.
Chemkart India Limited invested ₹97.90 lakh in its wholly owned subsidiary Easy Raw Materials Private Limited through a rights issue at ₹53.50 per share, the company said in a ScanX report on October 27, 2026. The capital is earmarked for commissioning the subsidiary's manufacturing unit.
Chemkart's Rights Issue Terms For Easy Raw Materials
The investment involved allotting 1,83,000 equity shares of face value ₹10 each at an issue price of ₹53.50 per share, according to the report. Chemkart made the investment on October 27, 2026, and disclosed it to BSE under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Chemkart said the infusion is a further step toward using proceeds from its IPO prospectus dated July 10, 2025 for the subsidiary's operational setup. Easy Raw Materials, incorporated in 2020, trades pharma products and nutritional supplements. As of March 31, 2026, the subsidiary reported nil turnover and a loss after tax of ₹59.47 lakh, with net worth of ₹578.60 lakh before the new capital. Paid-up capital now stands at ₹9.99 crore post-allotment, and Chemkart holds 100% of the subsidiary after the allotment.
Because Easy Raw Materials is a wholly owned subsidiary, the transaction qualifies as a related party transaction but is conducted at arm's length, the company said. No governmental or regulatory approvals were required for the investment.
Easy Raw Materials Funding In Company Records
Earlier capital moves into the subsidiary appear in company records on akta.pro. Chemkart invested Rs 1.00 Crore in Easy Raw Materials via a rights issue on June 17, 2026, allotting 10,00,000 equity shares at Rs 10 each to fund a manufacturing unit. The same records show Chemkart infused Rs 10 lakh into wholly owned subsidiary Vinstar Biotech through a rights issue in June 2026 for capital and working capital needs.
| Date | Subsidiary | Amount | Instrument |
|---|---|---|---|
| June 17, 2026 | Easy Raw Materials | Rs 1.00 Crore | Rights issue, 10,00,000 shares at Rs 10 |
| June 2026 | Vinstar Biotech | Rs 10 lakh | Rights issue |
| October 27, 2026 | Easy Raw Materials | ₹97.90 lakh | Rights issue, 1,83,000 shares at ₹53.50 |
Earlier Chemkart Funding For Easy Raw Materials
Chemkart invested ₹1.30 crore in Easy Raw Materials through a rights issue in September 2026, allotting 13,00,000 shares at ₹10 each, ScanX reported. Those funds were also directed at commissioning the subsidiary's manufacturing unit, which reported nil turnover and net worth of ₹578.60 lakh as of March 31, 2026.
In June 2026, Chemkart invested ₹10 lakh in wholly owned subsidiary Vinstar Biotech through a rights issue to fund capital and working capital requirements, ScanX reported. Chemkart reported revenue of ₹99.60 crore for Q1FY27 in July 2026, with the EZRM manufacturing facility project on schedule, according to ScanX.